Dec
1
On the eve of the founding father, he refused to Taiwan, and into the national revolution, well-known generation, He is the mouth ", "100 colleagues, the mainstay in the cornerstone of the students' growth, His noble, medical practitioners rigorous, dares not falling out person... He is the son of the kuomintang, door, 78, shenyang military medical research group, shenyang military hospital, a former vice President ZhangXinSheng has described as "head to feet, and the whole heart for all patients" medicine. The son of legend handed in motherland mainland ZhangXinSheng was born in a family, a senior officer's nationalist kuomintang ZhangLiu cloud is the air force general In 1948 near the end, the kuomintang government into chaos, his father decided to family. The kremlin 17 ZhangXinSheng accept progress, and made the first choice of life: refuse transfer, insists on staying at the national central university, nanjing university medical college (now) to complete their education. In 1949, the liberation of the spring ZhangXinSheng gunfire began, nanjing (urge and discouraged, again rejected Taiwan's "urgent" cable, resolutely left mainland to adhere to. Today, the memories of the past 60 years ago, the body lying on his deathbed, 78 years old is still excited: "then revolutionary activities from underground to earth, we this a group of young students, at the age of seventeen arm in arm was walking in the street, sing songs, carefree, revolution, what also not afraid." A young man and arm to reporters, above the liberated areas, sings, "is fine days..." Still, the song of the year filled with revolutionary fervor. Since then, the ideal of personal ZhangXinSheng with country and national destiny tightly together. The ZhangXinSheng enlisted near to the first party organization submitting application. But nobody thought, his party, the road will be so long and hard. From 1951 to 1977, except for the first three years of the "cultural revolution", ZhangXinSheng was put on "reactionary academic authority" hat, thus involved every year to the organization submitting an application and thought report, during these years, he writes application have 1 stack up, because foot thick family background problem. That frustration, someone advised him: "so old age, also has to win a what? Would be a doctor's life." ZhangXinSheng not depressed, not discouraged, carefully replied: "the man is not only to mix a good life to live in the world, also should have the lofty spirit pursuit." After test commitment, grind faith like rock. After the end of the cultural revolution, hospital committee sent finded years of outstanding issues for the history ZhangXinSheng made the correct conclusion. In 1977, 46, February ZhangXinSheng finally realize the party's wish. To the lofty ideal, ZhangXinSheng persistentof 27 years! Responsible for patients with cardiac surgery patients The clock is a choice, the choice of responsibility In 1976, on August 1, with the medical team to ZhangXinSheng tangshan earthquake relief, because
Nov
29
New China net Beijing on November 27 special news (reporter prince's metal' Hunan) current, domestic and foreign lethal population most malignant tumor lung cancer being possible be called “in cancer king”. Beijing Tumour hospital radiotherapy branch innovation treatment idea, for the past ten years aims at “in the cancer the king”, uses the early lung cancer precise radiotherapy not to create cures the new technology, “to put double cures” and so on many kinds of advanced treatment methods to enhance the curative effect, the exploration attacks and captures the lung cancer the new pattern. According to this branch assistant director, physician-in-charge, postgraduate candidate Teacher Professor Zhu Guangying introduced that ten years ago, domestic “put when double cures” also still at starts the stage, this branch lung cancer study team aims at the Chinese lung cancer patient to the synchronization to put in the chemotherapy the chemotherapy tolerance dose unclear present situation, first then uses the method which according to the international standard hypothesis radiotherapy dosage the dosage increases progressively gradually, the exploration “puts double cures” the chemotherapy biggest tolerance dose, simultaneously explores the smallest effective dose, guaranteed that the patient quality of life, discovered the taxus mellow small dosage usage has the high curative effect many times, the related result publishes in the overseas influential specialized magazine. In recent years, Beijing Tumour hospital radiotherapy branch used internationally the standard computer center random device, studied 44 example partial later period non-cellule lung cancer the curative effect, the side effect, discovered that “the small dosage multiple usage” the short-term effectiveness will be 90.4%, was higher than every week the usage obviously 52.1%, but 3/4 level of white blood cell dropped the formation rate was 0%, was lower than every week the usage 26%, side effects and so on hemoglobin, blood platelet, esophagitis, radioactive pneumonia, asthenia were also lower than apply drugs the group every week. Had proven scientifically the taxus mellow many times small dosage usage both surpasses the single large dose usage in the curative effect and the patient quality of life two aspects. Professor Zhu Guangying and so on research has broken “the radiotherapy only has appeases the function” the traditional ideas, set up the modern precise radiotherapy to be possible to permanently cure the lung cancer the new concept, explored one to attack and capture the lung cancer the efficient path. In the early lung cancer radiotherapy aspect, this study team full use advanced radiotherapy equipment, the exploration not creates cures the new technology, 30 times reduces the radiotherapy time from the tradition to 2 to 4 times, the radiotherapy latter 1 year partial inverse amplification factor from 30% to 40% enhances to 90% about, by the method which not creates has achieved the surgery similar effect. The overseas experience also proved that after this fast precise radiotherapy, patient's 5 year survival rate and the surgery are similar. In convened the other day at the international lung cancer multi-disciplinary treatment forums, these medical achievement obtained including American president medical consultant domestic and foreign lung cancer expert's agreeing.
Nov
29
The peninsula metropolis newspaper on November 28 the news (by Jiao Gongsen) the Jimo youth Mr. Yang's mother contracted the lung cancer to fall ill, he and the father looked after the female patient in the hospital ward to be really inconvenient, but he was reading big girlfriend young Yang to ask for leave to the school, shouldered resolutely has considered the boyfriend mother's heavy burden. on 28th the morning, Mr. Yang's mother told the reporters, the son has the such good girlfriend, oneself “walk” when definitely will feel relieved. ??on 28th about 10:00 am, reporter in the Jimo People's Hospital hospital ward building saw when Yang Mr. mother Ms. Chang, before a young girl hospital bed, is stroking the Ms. Chang head to chat with her. Saw reporter, Ms. Chang lifts the hand to point at diligently is introducing that this was son's girlfriend young Yang. “do not look that she and the son has not married, but marries passing through the gate the daughter-in-law also to be better than!”Ms. Chang said. ??Mr. Yang told reporter, mother only then 45 years old, on February 5 is inspected this year has contracted the lung cancer. Because in the family the difficulty, the mother only lived in one week courtyard to go home, under every week in the family member accompanied rides the public transportation to make the chemotherapy to Qingdao's big hospital. On November 14, mother's condition aggravation, he and the father put all sorts of things together has borrowed 70,000 Yuan, delivered the hospital in hospital the mother. ??On November 15 afternoon, on Qingdao some institute big young Yang, asks for leave arrives at the hospital, looks after Ms. Chang. Young Yang told the reporters, oneself and Mr. Yang the family leaves not far, one year first two person starts to be in love, the sentiment is very good. Own present cannot help the boyfriend to share too many things, has to look after his mother devotedly, the Aunt Chang feces and urine needs on the bed to solve, oneself achievement female, looks after must be much more convenient than the man. Ms. Chang told the reporters, saw the son found the such good girlfriend, own was very at heart gratified, “walked” when definitely very much will feel relieved. k for leave looks after
Nov
27
New China net Beijing on November 27 special news (reporter prince's metal' Hunan) current, domestic and foreign lethal population most malignant tumor lung cancer being possible be called “in cancer king”. Beijing Tumour hospital radiotherapy branch innovation treatment idea, for the past ten years aims at “in the cancer the king”, uses the early lung cancer precise radiotherapy not to create cures the new technology, “to put double cures” and so on many kinds of advanced treatment methods to enhance the curative effect, the exploration attacks and captures the lung cancer the new pattern. According to this branch assistant director, physician-in-charge, postgraduate candidate Teacher Professor Zhu Guangying introduced that ten years ago, domestic “put when double cures” also still at starts the stage, this branch lung cancer study team aims at the Chinese lung cancer patient to the synchronization to put in the chemotherapy the chemotherapy tolerance dose unclear present situation, first then uses the method which according to the international standard hypothesis radiotherapy dosage the dosage increases progressively gradually, the exploration “puts double cures” the chemotherapy biggest tolerance dose, simultaneously explores the smallest effective dose, guaranteed that the patient quality of life, discovered the taxus mellow small dosage usage has the high curative effect many times, the related result publishes in the overseas influential specialized magazine. In recent years, Beijing Tumour hospital radiotherapy branch used internationally the standard computer center random device, studied 44 example partial later period non-cellule lung cancer the curative effect, the side effect, discovered that “the small dosage multiple usage” the short-term effectiveness will be 90.4%, was higher than every week the usage obviously 52.1%, but 3/4 level of white blood cell dropped the formation rate was 0%, was lower than every week the usage 26%, side effects and so on hemoglobin, blood platelet, esophagitis, radioactive pneumonia, asthenia were also lower than apply drugs the group every week. Had proven scientifically the taxus mellow many times small dosage usage both surpasses the single large dose usage in the curative effect and the patient quality of life two aspects. Professor Zhu Guangying and so on research has broken “the radiotherapy only has appeases the function” the traditional ideas, set up the modern precise radiotherapy to be possible to permanently cure the lung cancer the new concept, explored one to attack and capture the lung cancer the efficient path. In the early lung cancer radiotherapy aspect, this study team full use advanced radiotherapy equipment, the exploration not creates cures the new technology, 30 times reduces the radiotherapy time from the tradition to 2 to 4 times, the radiotherapy latter 1 year partial inverse amplification factor from 30% to 40% enhances to 90% about, by the method which not creates has achieved the surgery similar effect. The overseas experience also proved that after this fast precise radiotherapy, patient's 5 year survival rate and the surgery are similar. In convened the other day at the international lung cancer multi-disciplinary treatment forums, these medical achievement obtained including American president medical consultant domestic and foreign lung cancer expert's agreeing.
Nov
27
??Business society on November 27 news November is 9th “the global lung cancer attention month”. At present, the lung cancer already substituted for liver cancer to become our country first succeeding in the imperial civil service examinations malignant tumor. Statistical data which announces according to the medical department, in 2008, the malignant tumor has reached 166.97 in our country city area's mortality rate/100,000, occupies the total cause of death 27.12%. Our country lung cancer's mortality rate already reached as high as 30.83/100,000, compared 30 years ago grew nearly 5 times. Regardless in the city or in the village, the lung cancer already became “the first murderer”. The expert thought: Approximately some 87% lung cancer and smoking related, meanwhile has included the passive smoking risk. In the cigarette includes the benzene and pi and so on many kinds of carcinogens. Has the smoking custom lung cancer disease incidence rate to compare smoker high 10 times, the smoking quantity big disease incidence rate is not higher, does not compare smoker high 20 times. ????According to American IMS Healath data: in 2007, in the global seven big medicine market's 500 strong drugs, the target has amounted to more than 200 hundred million US dollars to the anti-tumor medicine market share, compared the last year to grow 27.05% same time, was higher than the global anti-tumor medicine market 19.94% rates of increment by far. But in 2008, although the international finance crisis's influence, the medicine market in the rigid demand and under the inertia development's impetus, the anti-tumor medicine market still displayed the strong trend to grow, has amounted to 48,189,000,000 US dollars, grew 15.54% compared to the same period. And, the target is at the position which to the anti-tumor medicine market by 29,000,000,000 US dollars sales volumes leads, compared the last year to grow 45% same time. The market analyst forecast that to 2015, the anti-tumor target will surpass 50,000,000,000 US dollars to the treatment medicine, the compound yearly rate reaches as high as 11%, and this domain will have 8 above new medicines to grow into “the heavy case bomb” the product. ??The target is on the rise to the medication ??At present, the anti-tumor target to the medicine is mainly the monoclonal antibody medicine, the small molecular medicine and the cell perishes weakly the induction medicine. Although the anti-tumor target is the same to the medicine and the ordinary anti-tumor medicine, similarly faces the pressure which the patent expires, however, the anti-tumor medicine far has not satisfied the variation treatment the market demand, thus becomes in the drugs market the highly regarded important propelling force. ??Connects rails gradually along with the domestic external use medicine market as well as the national medical service consumption level enhancement, the target also displays the strong rising to the anti-tumor medicine in the domestic sample hospital market the situation. The anti-tumor small member target has the high target tropism, the curative effect to the preparation remarkable, the untoward effect small characteristic, improved patient's survival quality, already became the clinical medication the future tendency and time the variety which focuses attention on. At present, anti-tumor small member target's to medicine in Iraqi horse Tini, distress Luo river Tini, extends Nepali Tini, lucky non-Tini, the Zola non-Nepal, to reach sand Tini, to pull handkerchief Tini and Nepali Luo river Tini already is the clinical principal variety. ??in 2008, the domestic 22 key urban sample hospital applies drugs the market use the anti-tumor small member target to the preparation, lucky non-Tini, distress Luo river Tini, Iraqi horse Tini, the Zola non-Nepal, extended the Nepali Tini 5 varieties to surpass more than 500,000,000 Yuan Renminbi, estimated that will surpass 1,000,000,000 Yuan market sizes to 2011.
??Lucky non-Tini commands troops ??Lucky non-Tini (Gefitinib) is British Asi the Advantage Kang Company develops the development the anti-tumor target to the small molecular medicine. in August, 2002, lucky non-Tini first took a non-cellule lung cancer treatment medicine to go on the market in Japan, commodity named “Iressa” (Yi Ruisha). in May, 2003, lucky non-Tini by the American FDA authorization, became by the platinum class cancer drug and many west taxus mellow chemotherapy invalid later period non-cellule lung cancer patient's three Shan Yao treats the medicine. At present, in the US, Japan, Australia and China, lucky non-Tini is authorized to use in treating the later period or the transferability non-cellule lung cancer. ??After lucky non-Tini goes on the market, the first year has obtained 0.67 US dollars achievements, the analyst had predict that 5 years later may amount to 659,000,000 US dollars in US's sales volume. However, the lucky non-Tini market development winding influence, as well as the anti-tumor target to the small molecular medicine distress Luo river Tini strong trend competition, Yi Ruisha the market once suffered setbacks in Europe and America, the performance fluctuation is unconstrained. in 2008 the lucky non-Tini sales volume was still 265,000,000 US dollars, but the last year grew 11.34% compared to the same period. in 2009 in the first half of the year is 143,000,000 US dollars, the rate of increment is 14%. Along with the anti-tumor target to the treatment experience's accumulation, as well as to the sensitive crowd's determination, lucky non-Tini demonstrated to the different race lung cancer patient's EGFR sudden change certain activeness, its curative effect has surpassed a commonly used chemotherapy method, but regarding sudden change patient effect really micro. Therefore, on July 1, 2009, European Union authorizes lucky non-Tini to use in the adult partial later period which or transferability non-cellule lung cancer patient's, two officially EGFR changes suddenly and a three treatment medication, enabled the molecular target to obtain consolidated to the treatment in certain common tumor treatment status. ??in 2005, Asi advantage Kang company's lucky non-Tini enters our country market, obtains the SFDA authorization to use in passing through the chemotherapy the partial later period or the transferability non-cellule lung cancer, but not yet authorizes to take the later period non-cellule lung cancer at present a medication. But in the target to under the treatment superiority, promoted Yi Ruisha the clinical use. in 2005 the sample hospital applies drugs the market to top 20,000,000 Yuan, afterward 4 year average annual rate of growth has surpassed 100%. in 2008 our country 22 city sample hospital medication amount has surpassed 200,000,000 Yuan, reaches 417,400 pieces with the dose. It is reported that in 2006, our country formulates "the American State-run Synthesis Cancer Network (NCCN) the Non-Cellule Lung cancer Clinical practice Guide (the Chinese Version)" has recommended lucky non-Tini to take the later period non-cellule lung cancer two and three standard therapeutic schedule, lucky non-Tini becomes the domestic anti-tumor small member target to the preparation “the lead goat”. ??Distress Luo river Tini promising youth ??Distress Luo river Tini (erlotinib) is the gene peaceful gram, Roche and the OSI Pharmaceutical company unit exploitation one kind of small molecular anticancer treatment medicine, the commodity named “Tarceva” (west Trow triumphant/him health). in November, 2004 and in September, 2005 through American FDA and European EMEA examination, already in global 70-80 country going on the market. Under many clinical research's impetuses, the distress Luo river Tini market advances in great strides, from initial two, three treatments expand to a medication, the maintenance treatment and the sequential treatment and so on many stages, enabled the later period non-cellule lung cancer treatment to have many choices. In the recent 10 years, distress Luo river Tini is also the American FDA authorization first cancer of the pancreas treats the medicine, can pointed affect in the pancreatic neoplasm cell, suppresses it to form, the growth, lengthens the patient lifetime. ??According to the American Montefiore medicine center introduced that distress Luo river Tini has the oral administration dosage to be small, the blood plasma medicine exposition density is high and the half-life short characteristic, will be every day redundant for the medicine will not cause the medicine accumulation. After distress Luo river Tini enters clinical, the market start is quick, in 2007 has cultivated “the heavy case bomb” the variety, in 2008, the global market has amounted to 1,470,000,000 US dollars, grew 39.47% compared to the same period. ??in 2007, SFDA authorizes Swiss Roche Pharma (Schweiz) company's distress Luo river Tini to enter our country market, loaded separately the sale by the Shanghai Roche Company, the going on the market first year has sold 53,780,000 Yuan in 16 urban sample hospital, in 2008 applied drugs the amount to surpass 108,000,000 Yuan, grew 101.26% compared to the same period, applied drugs in the first quarter looking from 2009, was still maintaining the swift growth situation. ?? “Geleg health” spring snow ??Methylsulfonic acid Iraq horse Tini (Imatinib Mesylate) is the tyrosine activating enzyme inhibitor class medicine which Swiss China Corporation researches and develops. on May 10, 2001, Iraqi horse Tini by “had the unprecedented anti-tumor mechanism” to obtain American FDA the express examination, the commodity named “Gleevec” (the Geleg health). At first uses in Alpha - the interferon for the medicine defeat protoblast crisis sickness time, chronic illness time, accelerating sickness time the granular cell leukemia (chronic marrow leukemia) the clinical care medication. Afterward, American FDA authorized Iraqi horse Tini second to be suitable sickness, used in treating the gastro-intestinal tract mesenchymal cytoma's treatment. After global widespread clinical use, has obtained the medical arena strong approval, obtained American FDA officially in December 23, 2002 the blanket approval, the authorization takes a chronic granular cell leukemia treatment medication, thus is been honored as by the medical arena the recent years “had the significant unprecedentedness” the anti-tumor target to the small molecular oral administration medicine preparation. Iraqi horse Tini after countries and so on US, European Union and Japan attains approves the achievement rare sickness medication, already in the world more than 80 countries approved to use in the chronic granular cell leukemia, moreover also approves in many developed countries and the developing country to use in the gastro-intestinal tract mesenchymal cytoma's treatment. ??Along with Iraqi horse Tini market development, moreover takes advantage of its soaring price, has obtained in the past 165,000,000 US dollar prominent good results in going on the market, goes on the market for 3 years later, has cultivated into “the heavy case bomb” the level medicine. At present, this medicine in the world nearly hundred countries, the local sale, in 2008 the Geleg health global market has amounted to 3,670,000,000 US dollars, the last year grew 20.33%,2009 year the first half of the year Geleg health sales volume is 1,884,000,000 US dollars compared to the same period, only compared the last year to grow 3%. ??Iraqi horse Tini obtained SFDA in April 17, 2002 the production written instructions to a subordinate, entered the hospital for the first time in the third quarter in the same year, after product entering the market, started quickly, under the soaring medicine price's actuation, is applied drugs the market in the sample hospital to be in the steady growth situation. in 2007 applies drugs the amount to surpass 60,000,000 Yuan, in 2008 the last year grew 30.85% compared to the same period, the nearly 90,000,000 Yuan, had estimated that in 2009 will apply drugs the market in the domestic 22 key urban sample hospital the sales volume to surmount hundred million Yuan critical junctions. ??The variety which the global anti-tumor target is enters new century goes on the market after the small molecular chemistry medicine, its function mechanism, multi-target expansion and security still during clinical exploration, after many medicine new indications are authorized uses in clinical, impelled the market sale growth, but the untoward effect exposed gradually also causes to cause the market fluctuation. The domestic target is late to the small molecular new medicine research and development start, still did not have original new medicine going on the market. At present, the domestic market mainly dominates by the transnational pharmaceutical industry's expensive import medicine. ??In recent years, the target also gradually became the domestic scientific research courtyard institute and the Production enterprise research direction to the anti-tumor medicine. It is reported that the home is developing in the development the anti-tumor small member target to enter toward the new medicine clinical, like Zhejiang Beida pharmaceutical industry development treatment lung cancer small member target to medicine Eck Tini, with a yellow medicine chemistry kind of target to anticancer treatment new medicine rope every Tini (Sulfatinib), fu kui Tini (Fruquintinib) and so on. Along with the domestically produced target to small molecular anti-tumor medicine's being published, will further advance the anti-tumor medicine product mix by the outstanding curative effect and the reasonable price the adjustment and the market development. (Cai Deshan)
??Lucky non-Tini commands troops ??Lucky non-Tini (Gefitinib) is British Asi the Advantage Kang Company develops the development the anti-tumor target to the small molecular medicine. in August, 2002, lucky non-Tini first took a non-cellule lung cancer treatment medicine to go on the market in Japan, commodity named “Iressa” (Yi Ruisha). in May, 2003, lucky non-Tini by the American FDA authorization, became by the platinum class cancer drug and many west taxus mellow chemotherapy invalid later period non-cellule lung cancer patient's three Shan Yao treats the medicine. At present, in the US, Japan, Australia and China, lucky non-Tini is authorized to use in treating the later period or the transferability non-cellule lung cancer. ??After lucky non-Tini goes on the market, the first year has obtained 0.67 US dollars achievements, the analyst had predict that 5 years later may amount to 659,000,000 US dollars in US's sales volume. However, the lucky non-Tini market development winding influence, as well as the anti-tumor target to the small molecular medicine distress Luo river Tini strong trend competition, Yi Ruisha the market once suffered setbacks in Europe and America, the performance fluctuation is unconstrained. in 2008 the lucky non-Tini sales volume was still 265,000,000 US dollars, but the last year grew 11.34% compared to the same period. in 2009 in the first half of the year is 143,000,000 US dollars, the rate of increment is 14%. Along with the anti-tumor target to the treatment experience's accumulation, as well as to the sensitive crowd's determination, lucky non-Tini demonstrated to the different race lung cancer patient's EGFR sudden change certain activeness, its curative effect has surpassed a commonly used chemotherapy method, but regarding sudden change patient effect really micro. Therefore, on July 1, 2009, European Union authorizes lucky non-Tini to use in the adult partial later period which or transferability non-cellule lung cancer patient's, two officially EGFR changes suddenly and a three treatment medication, enabled the molecular target to obtain consolidated to the treatment in certain common tumor treatment status. ??in 2005, Asi advantage Kang company's lucky non-Tini enters our country market, obtains the SFDA authorization to use in passing through the chemotherapy the partial later period or the transferability non-cellule lung cancer, but not yet authorizes to take the later period non-cellule lung cancer at present a medication. But in the target to under the treatment superiority, promoted Yi Ruisha the clinical use. in 2005 the sample hospital applies drugs the market to top 20,000,000 Yuan, afterward 4 year average annual rate of growth has surpassed 100%. in 2008 our country 22 city sample hospital medication amount has surpassed 200,000,000 Yuan, reaches 417,400 pieces with the dose. It is reported that in 2006, our country formulates "the American State-run Synthesis Cancer Network (NCCN) the Non-Cellule Lung cancer Clinical practice Guide (the Chinese Version)" has recommended lucky non-Tini to take the later period non-cellule lung cancer two and three standard therapeutic schedule, lucky non-Tini becomes the domestic anti-tumor small member target to the preparation “the lead goat”. ??Distress Luo river Tini promising youth ??Distress Luo river Tini (erlotinib) is the gene peaceful gram, Roche and the OSI Pharmaceutical company unit exploitation one kind of small molecular anticancer treatment medicine, the commodity named “Tarceva” (west Trow triumphant/him health). in November, 2004 and in September, 2005 through American FDA and European EMEA examination, already in global 70-80 country going on the market. Under many clinical research's impetuses, the distress Luo river Tini market advances in great strides, from initial two, three treatments expand to a medication, the maintenance treatment and the sequential treatment and so on many stages, enabled the later period non-cellule lung cancer treatment to have many choices. In the recent 10 years, distress Luo river Tini is also the American FDA authorization first cancer of the pancreas treats the medicine, can pointed affect in the pancreatic neoplasm cell, suppresses it to form, the growth, lengthens the patient lifetime. ??According to the American Montefiore medicine center introduced that distress Luo river Tini has the oral administration dosage to be small, the blood plasma medicine exposition density is high and the half-life short characteristic, will be every day redundant for the medicine will not cause the medicine accumulation. After distress Luo river Tini enters clinical, the market start is quick, in 2007 has cultivated “the heavy case bomb” the variety, in 2008, the global market has amounted to 1,470,000,000 US dollars, grew 39.47% compared to the same period. ??in 2007, SFDA authorizes Swiss Roche Pharma (Schweiz) company's distress Luo river Tini to enter our country market, loaded separately the sale by the Shanghai Roche Company, the going on the market first year has sold 53,780,000 Yuan in 16 urban sample hospital, in 2008 applied drugs the amount to surpass 108,000,000 Yuan, grew 101.26% compared to the same period, applied drugs in the first quarter looking from 2009, was still maintaining the swift growth situation. ?? “Geleg health” spring snow ??Methylsulfonic acid Iraq horse Tini (Imatinib Mesylate) is the tyrosine activating enzyme inhibitor class medicine which Swiss China Corporation researches and develops. on May 10, 2001, Iraqi horse Tini by “had the unprecedented anti-tumor mechanism” to obtain American FDA the express examination, the commodity named “Gleevec” (the Geleg health). At first uses in Alpha - the interferon for the medicine defeat protoblast crisis sickness time, chronic illness time, accelerating sickness time the granular cell leukemia (chronic marrow leukemia) the clinical care medication. Afterward, American FDA authorized Iraqi horse Tini second to be suitable sickness, used in treating the gastro-intestinal tract mesenchymal cytoma's treatment. After global widespread clinical use, has obtained the medical arena strong approval, obtained American FDA officially in December 23, 2002 the blanket approval, the authorization takes a chronic granular cell leukemia treatment medication, thus is been honored as by the medical arena the recent years “had the significant unprecedentedness” the anti-tumor target to the small molecular oral administration medicine preparation. Iraqi horse Tini after countries and so on US, European Union and Japan attains approves the achievement rare sickness medication, already in the world more than 80 countries approved to use in the chronic granular cell leukemia, moreover also approves in many developed countries and the developing country to use in the gastro-intestinal tract mesenchymal cytoma's treatment. ??Along with Iraqi horse Tini market development, moreover takes advantage of its soaring price, has obtained in the past 165,000,000 US dollar prominent good results in going on the market, goes on the market for 3 years later, has cultivated into “the heavy case bomb” the level medicine. At present, this medicine in the world nearly hundred countries, the local sale, in 2008 the Geleg health global market has amounted to 3,670,000,000 US dollars, the last year grew 20.33%,2009 year the first half of the year Geleg health sales volume is 1,884,000,000 US dollars compared to the same period, only compared the last year to grow 3%. ??Iraqi horse Tini obtained SFDA in April 17, 2002 the production written instructions to a subordinate, entered the hospital for the first time in the third quarter in the same year, after product entering the market, started quickly, under the soaring medicine price's actuation, is applied drugs the market in the sample hospital to be in the steady growth situation. in 2007 applies drugs the amount to surpass 60,000,000 Yuan, in 2008 the last year grew 30.85% compared to the same period, the nearly 90,000,000 Yuan, had estimated that in 2009 will apply drugs the market in the domestic 22 key urban sample hospital the sales volume to surmount hundred million Yuan critical junctions. ??The variety which the global anti-tumor target is enters new century goes on the market after the small molecular chemistry medicine, its function mechanism, multi-target expansion and security still during clinical exploration, after many medicine new indications are authorized uses in clinical, impelled the market sale growth, but the untoward effect exposed gradually also causes to cause the market fluctuation. The domestic target is late to the small molecular new medicine research and development start, still did not have original new medicine going on the market. At present, the domestic market mainly dominates by the transnational pharmaceutical industry's expensive import medicine. ??In recent years, the target also gradually became the domestic scientific research courtyard institute and the Production enterprise research direction to the anti-tumor medicine. It is reported that the home is developing in the development the anti-tumor small member target to enter toward the new medicine clinical, like Zhejiang Beida pharmaceutical industry development treatment lung cancer small member target to medicine Eck Tini, with a yellow medicine chemistry kind of target to anticancer treatment new medicine rope every Tini (Sulfatinib), fu kui Tini (Fruquintinib) and so on. Along with the domestically produced target to small molecular anti-tumor medicine's being published, will further advance the anti-tumor medicine product mix by the outstanding curative effect and the reasonable price the adjustment and the market development. (Cai Deshan)
